CGIM
HRMY icon

Cannon Global Investment Management’s Harmony Biosciences HRMY Stock Holding History

Cannon Global Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,000
Closed -$307K – 48
2021
Q3 		$307K Buy
+8,000
New +$258K 0.46% 42

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Cannon Global Investment Management's HRMY Position: Q4 2021 in Review

Cannon Global Investment Management sold out of Harmony Biosciences (HRMY) in Q4 2021, closing a stake of 8,000 shares — an estimated $307K sold.

Cannon Global Investment Management first reported a position in HRMY in Q3 2021 and held it in 1 quarter. The position peaked at $307K in Q3 2021. 147 funds tracked by Wall St. Rank hold HRMY as of Q4 2021.

  • Cannon Global Investment Management reported no remaining Harmony Biosciences position as of Q4 2021 after selling out during the quarter.
  • Cannon Global Investment Management sold 8,000 Harmony Biosciences shares in Q4 2021, an estimated $307K.
  • Cannon Global Investment Management first reported a position in Harmony Biosciences in Q3 2021 and held it in 1 quarter.
  • Cannon Global Investment Management's Harmony Biosciences position peaked at $307K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2021.

Based on Cannon Global Investment Management's 13F filing for Q4 2021, filed 4 Feb 2022.